CNTA Centessa Net earnings per share for the last 12 months

Centessa Pharmaceuticals (CNTA) relies on high-cost R&D developments in neurology with the potential for monopoly scaling. The current trailing twelve-month EPS value provided by the GURU.Markets website demonstrates profit dynamics where -1.76 determines the current status of the parameter. Revenues are based on insurance payouts for the treatment of rare pathologies, while research stability is guaranteed by a decentralized network of international logistics partners.
Centessa Corp - analytical breakdowns and key metrics (CNTA)

Since Centessa Pharmaceuticals (CNTA) fully delegates drug development to external contractors, its financial performance depends directly on the efficiency of outsourcing cost management. By analyzing the rolling net income per share, an investor can see the business's final annual return adjusted for issuance volume, allowing for an assessment of the real value of each stake in this high-risk biotech asset.